1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
H. Lundbeck A/S

H. Lundbeck A/S

HLBBF
H. Lundbeck A/SUS flagOther OTC
6.96
USD
- -
- -
5.52BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
77.79
68.63
74.28
79.29
87.52
89.97
87.36
88.92
16.41
18.38
20.07
22.19
24.83
26.19
Basic EPS, GAAP
4.36
-0.78
-28.98
6.14
13.29
19.67
11.64
7.96
1.33
1.93
2.31
3.17
3.22
3.91
Free Cash Flow per Basic Share
11.45
0.31
-14.04
14.12
16.81
26.56
10.9
16.9
1.67
2.72
3.61
2.78
4.9
5.85
Dividend per Share
2
2.77
- -
- -
2.45
8
12
4.1
0.5
0.4
0.58
0.7
0.95
1.15
Book Value per Share
68.71
68.87
44.53
49.12
61.32
71.71
84.46
85.42
92.02
20.93
22.22
25.23
25.1
27.07
Tangible Book Value per Share
22.45
4.36
-5.11
4.33
23.24
31.34
-47.67
-29.01
-22.51
-1.73
1.36
-16.16
-10.96
-9.23
Basic Weighted Avg Shares
196
196
196
197
198
199
199
199
993
993
992
991
992
991
Sales/Revenue/Turnover
15,258
13,468
14,594
15,634
17,286
17,875
17,358
17,672
16,299
18,246
19,912
22,004
24,630
25,960
Operating Margin (%)
10.48
0.74
-46.7
14.66
25.8
28.3
20.02
11.26
12.33
15.63
16.05
14.86
21.42
21.8
Depreciation Expense
- -
1,453
7,026
1,554
- -
- -
1,670
2,793
1,710
1,811
2,012
1,876
1,865
- -
Net Income, GAAP
855
-153
-5,694
1,211
2,624
3,907
2,313
1,581
1,318
1,916
2,290
3,143
3,192
3,880
Effective Tax Rate (%)
41.92
- -
- -
43.86
38.65
26.13
23.56
17.05
16.64
22.55
23.49
15.49
28.86
27.73
Profit Margin (%)
5.6
-1.14
-39.02
7.75
15.18
21.86
13.33
8.95
8.09
10.5
11.5
14.28
12.96
14.95
Working Capital
4,845
2,184
-88
-252
2,365
4,073
-1,242
93
-206
3,213
5,299
4,430
3,930
3,435
LT Debt
2,141
3,259
3,687
1,708
57
- -
7,499
5,813
5,236
5,491
4,065
16,611
11,580
9,346
Total Equity
13,481
13,526
8,785
9,694
12,181
14,251
16,782
16,973
18,279
20,779
22,045
25,010
24,903
26,865
Return on Invested Capital (%)
6.04
- -
- -
10.6
22.82
28.14
12.9
6.3
6.76
8.67
9.12
8.04
9.48
10.91
Return on Capital (%)
6.62
- -
- -
11.46
23.64
29.5
11.63
6.76
5.97
7.99
8.87
9.54
9.09
10.47
Return on Common Equity (%)
6.41
-1.13
-51.04
13.11
23.99
29.56
14.91
9.37
7.48
9.81
10.69
13.36
12.79
15.2

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
74
74
71
LT Borrowings
11,185
10,446
8,955
LT Finance Leases
395
408
391
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
992
992
992
Market Capitalization
43,379
39,773
42,854

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
12,783
12,647
12,807
Cash, Cash Equivalents & STI
3,433
1,956
2,196
Accounts Receivable, Net
3,605
6,092
6,227
Inventories
4,473
4,599
4,384
Total Current Liabilities
8,853
8,991
9,372
Payables & Accruals
- -
- -
- -
ST Debt
74
74
71
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.24%
8.1%
-0.43%
Free Cash Flow
-2.87%
19.58%
76.13%
Net Income, GAAP
5.89%
17.41%
1.56%
Sales/Revenue/Turnover
5.58%
7.15%
11.93%
Total Cash Common Dividend
- -
8.46%
35.88%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,288
5,453
5,722
5,541
22,004
2025
6,235
6,023
6,279
6,093
24,630
2026
7,125
6,463
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.01
0.78
0.78
- -
3.17
2025
1.13
0.95
1.11
- -
3.22
2026
1.67
1.16
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.7
- -
- -
- -
0.7
2025
0.95
- -
- -
- -
0.95
2026
1.15
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Charl van Zyl
Full Time Employees
5,214
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Ottiliavej 9 Valby CR Denmark 2500
IPO Date
Jul 13, 2022
Website
lundbeck.com
Similar Companies
Shineco, Inc. (TYHT)
PT Pyridam Farma Tbk (PYFA.JK)
TPCO Holding Corp. (GRMWF)
Leef Brands Inc. (ICNAF)
Glenmark Life Sciences Limited (GLS.NS)
Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ)
Business
H. Lundbeck A/S, a Denmark-based international pharmaceutical company founded in 1915 and headquartered in Valby, Copenhagen, specializes in the research, development, manufacturing, marketing, and sale of innovative therapeutics for brain diseases including psychiatric and neurological disorders. The company operates in more than 50 countries with production facilities in Denmark, France, and Italy, research centers in Denmark and the USA, and products registered in over 100 countries worldwide. Its core portfolio encompasses treatments across multiple disease areas: for Parkinson's disease, Azilect (rasagiline); for alcohol dependence, Selincro (nalmefene); for Alzheimer's disease, Ebixa/Ebix/Abixa/Memantine Merz (memantine); for migraine, Vyepti (eptinezumab); for epilepsy, Sabril (vigabatrin), Onfi/Frisium (clobazam); for depression and anxiety, Rexulti/Rxulti (brexpiprazole), Brintellix/Trintellix/Fonksera/Vortioson/Vurtuoso (vortioxetine), Cipralex/Lexapro/Sipralexa/Seroplex/Entact/Lepax/Premalex/Prilect/Esipram/Esertia/Rhea Escitalopram (escitalopram oxalate), Cipramil/Seropram/Cipram/Sepram/Celexa/Elopram/Prisdal (citalopram), Deanxit (flupentixol + melitracene), Noritren/Nortrilen/Sensaval (nortriptyline), and Saroten/Sarotex/Redomex/Sarotena (amitriptyline); for psychosis, Rexulti/Rxulti (brexpiprazole), Abilify Maintena (aripiprazole), Serdolect (sertindole), Cisordinol/Clopixol/Ciatyl-Z (zuclopenthixol), Cisordinol Depot/Clopixol Depot/Ciatyl-Z Depot (zuclopenthixol decanoate), Fluanxol Depot/Depixol/Fluanxol LP/Fluanxol Retard (cis(Z)-flupentixol decanoate), Fluanxol/Fluanxol Mite/Depixol (flupentixol), Truxal (chlorprothixene), and Cisordinol-Acutard/Clopixol-Acutard/Clopixol-Acuphase/Ciatyl-Z-Acuphase (zuclopenthixol acetate); and for other indications, Northera (droxidopa). In recent developments, Lundbeck completed the acquisition of Longboard Pharmaceuticals in 2024 for approximately $2.6 billion, significantly enhancing its neuroscience pipeline; announced a restructuring of commercial operations impacting over 600 international employees to adopt a partner-model for global markets; and raised its full-year 2025 financial guidance for revenue and adjusted EBITDA growth at constant exchange rates, supported by strong year-to-date revenue increases driven by key brands like Vyepti. The Lundbeck Foundation maintains majority ownership of approximately 69%.

Company News

Company News APIChatGPT

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript

  • wsj.com

    H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Q3 2025 Earnings Call Transcript

  • prnewswire.com

    Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan